XDG3:XETRA:XETRA-Xtrackers MSCI Global SDG 3 Good Health UCITS ETF 1C USD EUR (EUR)

ETF | Others |

Last Closing

USD 32.72

Change

+0.22 (+0.68)%

Market Cap

USD 0.15B

Volume

221.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-01 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.41 (+0.79%)

USD 501.76B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.13 (+0.77%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.26 (+0.97%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.21 (+0.73%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.10 (+0.41%)

USD 157.79B
8R80:XETRA Amundi Index Solutions - Amund..

+0.02 (+0.01%)

USD 101.19B
JARI:XETRA Amundi Index Solutions - Amund..

+0.01 (+0.01%)

USD 100.74B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.40 (+0.78%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

+0.19 (+0.20%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+1.48 (+0.27%)

USD 80.38B

ETFs Containing XDG3:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.20% 66% D+ 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.20% 66% D+ 66% D+
Trailing 12 Months  
Capital Gain 18.19% 51% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.19% 50% F 53% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 3.07% N/A N/A 44% F
Dividend Return 3.07% N/A N/A 42% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 6.26% N/A N/A 82% B
Risk Adjusted Return 48.96% N/A N/A 57% F
Market Capitalization 0.15B 39% F 35% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.